Kura Oncology (KURA) Share-based Compensation (2014 - 2026)

Kura Oncology (KURA) has 13 years of Share-based Compensation data on file, last reported at $8.4 million in Q1 2026.

• Quarterly Share-based Compensation rose 7.32% year-over-year to $8.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.7 million (up 13.41% YoY) and the FY2025 annual result came in at $37.1 million, up 9.47% from the prior year.
• Share-based Compensation slipped to $8.4 million in Q1 2026 per KURA's latest filing, from $11.4 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $11.4 million in Q4 2025 and bottomed at $6.4 million in Q3 2022.
• The 5-year median for Share-based Compensation is $7.2 million (2023), against an average of $7.9 million.
• Peak annual rise in Share-based Compensation reached 31.73% in 2025, while the deepest fall reached 17.57% in 2025.
• Tracing KURA's Share-based Compensation over 5 years: stood at $6.8 million in 2022, then increased by 5.32% to $7.2 million in 2023, then increased by 20.43% to $8.6 million in 2024, then soared by 31.53% to $11.4 million in 2025, then declined by 25.86% to $8.4 million in 2026.
• Per Business Quant, the three latest KURA Share-based Compensation figures stand at $8.4 million (Q1 2026), $11.4 million (Q4 2025), and $11.0 million (Q3 2025).

Peer Comparison